The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Maksimov K.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Starkova M.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Bagdasarova D.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Volchenko N.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Mazo M.L.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Surkova V.S.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Zikiryakhodzhaev A.D.

I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Russia;
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Russia;
Peoples’ Friendship University of Russia

Can surgical treatment in the future be abandoned in breast cancer patients with a complete morphopathological response after neoadjuvant chemotherapy?

Authors:

Maksimov K.V., Starkova M.V., Bagdasarova D.V., Volchenko N.N., Mazo M.L., Surkova V.S., Zikiryakhodzhaev A.D.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2022;11(6): 73‑79

DOI: 10.17116/onkolog20221106173

Read: 1666 times

Download PDF (RU)
Contact the author
Table of contents

CAN SURGICAL TREATMENT IN THE FUTURE BE ABANDONED IN BREAST CANCER PATIENTS WITH A COMPLETE MORPHOPATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY?
CAN SURGICAL TREATMENT IN THE FUTURE BE ABANDONED IN BREAST CANCER PATIENTS WITH A COMPLETE MORPHOPATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY?

To cite this article:

Maksimov KV, Starkova MV, Bagdasarova DV, Volchenko NN, Mazo ML, Surkova VS, Zikiryakhodzhaev AD. Can surgical treatment in the future be abandoned in breast cancer patients with a complete morphopathological response after neoadjuvant chemotherapy? P.A. Herzen Journal of Oncology. 2022;11(6):73‑79. (In Russ.)
https://doi.org/10.17116/onkolog20221106173

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Pelvic recu­rrences of ovarian cancer: sono­graphic visualization and magnetic reso­nance imaging. P.A. Herzen Journal of Onco­logy. 2024;(5):31-39
Capsular contracture after reco­nstructive plastic surgery for breast cancer. P.A. Herzen Journal of Onco­logy. 2024;(6):78-83
Free nipple-areolar complex grafting combined with reco­nstruction for unavoidable mastectomy. Plastic Surgery and Aesthetic Medi­cine. 2024;(4):60-64
Breast reco­nstruction after single-stage auto­logous reco­nstruction and subsequent flap lipo­necrosis. Plastic Surgery and Aesthetic Medi­cine. 2024;(4):77-83
The first expe­rience of using a biodegradable collagen matrix for the prevention of contour defo­rmation of the breast after sectoral rese­ction for a benign formation. Plastic Surgery and Aesthetic Medi­cine. 2024;(4):84-90
Non-invasive auto­mated methods for the diagnosis of periorbital skin tumors. Russian Annals of Ophthalmology. 2024;(5):137-145
NDRG1 protein expression in breast cancer samples, rela­tionship with lymph nodes meta­stasis. Russian Journal of Archive of Pathology. 2024;(6):36-42
Impact of tumor size on actuarial survival of patients with primary breast sarcoma: a case-control study. Piro­gov Russian Journal of Surgery. 2024;(12):38-43
Asse­ssment of risk factors for breast cancer deve­lopment in women living in the Sara­tov region. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):100-106
Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in anti­tumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143
Abstract:

Breast cancer occupies a leading position in the structure of the incidence of malignant neoplasms among the female population. Over time, surgical and medical treatments for patients with breast cancer have undergone various changes. The main trend in drug treatment is a personalized approach to choosing therapy; this allows the volume of surgical treatment to be decreased in the future. Complete resorption of the primary tumor is the most debated issue relating to the need for surgical treatment; however, the lack of accurate diagnostic methods cannot make a single conclusion regarding this problem. The literature review includes an analysis of studies conducted on this topic in 1980 to 2021. Despite a large number of instrumental diagnostic techniques, histological verification of the residual tumor bed remains the most accurate method today. For a more accurate bed assessment, it is necessary to use a combination of the methods: vacuum aspiration biopsy and fine needle aspiration biopsy.

Keywords:

breast cancer
neoadjuvant polychemotherapy
multipoint biopsy
vacuum aspiration biopsy
mammography
breast MRI
ultrasound
therapeutic pathomorphism
complete resorption

Authors:

Maksimov K.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Starkova M.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Bagdasarova D.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Volchenko N.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Mazo M.L.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Surkova V.S.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Zikiryakhodzhaev A.D.

I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Russia;
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Russia;
Peoples’ Friendship University of Russia

Received:

20.07.2022

Accepted:

01.08.2022

Close metadata

References:

  1. Breast [Electronic resource]. Globocan. 2020. https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf
  2. Kaprin AD, Starinskii VV, Shakhzadova AO. The state of oncological care for the population of Russia in 2021. M.: MNIOI im. P.A. Hertsena — filial FGBU «NMITs radiologii» of the Ministry of Health of the Russian Federation; 2022.
  3. Grushina TI, Zikiryakhodzhaev AD, Starkova MV. Experience in using the International Classification of Functioning, Disability and Health in patients with breast cancer after surgical treatment. P.A. Herzen Journal of Oncology. 2018;7(5):21-32. (In Russ.). https://doi.org/10.17116/onkolog2018705121
  4. Grushina TI, Tkachenko GA. Psychological distress in patients with breast cancer after different antitumor treatments. Tumors of female reproductive system. 2016;12(1):56-62. (In Russ.). https://doi.org/10.17650/1994-4098-2016-12-1-56-62
  5. Basik M, Costantino JP, De Los Santos JF, Umphrey H, Julian TB, Mamounas EP, White JR, Lucas PC, Wagner JL, Tjoe JA, et al. Abstract OT1-09-01: phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic response in patients with clinical/radiological complete response after neoadjuvant chemotherapy in order to explore the feasibility of breast-conserving treatment without surgery: NRG Oncology BR005. Cancer Res. 2019;79(4 suppl):OT1-09-01.  https://doi.org/10.1158/1538-7445.SABCS18-OT1-09-01
  6. Liu M, Yang Y, Xie F, Guo J, Wang S, Yang H, Wang S. Could axillary clearance be avoided in clinically node-negative breast cancer patients with positive nodes diagnosed by ultrasound guided biopsy in the post-ACOSOG Z0011 era? PLoS One. 2019;14(1):e0210437. https://doi.org/10.1371/journal.pone.0210437
  7. Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, Győrffy B, Kásler M, Mátrai Z. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla-surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672-679.  https://doi.org/10.1016/j.ejso.2016.12.011
  8. Hennigs A, Riedel F, Marmé F, Sinn P, Lindel K, Gondos A, Smetanay K, Golatta M, Sohn C, Schuetz F, et al. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat. 2016;160(3):491-499.  https://doi.org/10.1007/s10549-016-4016-4
  9. Lee HB, Han W, Kim SY, Cho N, Kim KE, Park JH, Ju YW, Lee ES, Lim SJ, Kim JH, et al. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial. Breast Cancer Res Treat. 2020;182(1):97-105.  https://doi.org/10.1007/s10549-020-05678-3
  10. Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170(3):559-567.  https://doi.org/10.1007/s10549-018-4801-3
  11. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342-3354. https://doi.org/10.1016/j.ejca.2012.05.023
  12. Rauch GM, Kuerer HM, Adrada B, Santiago L, Moseley T, Candelaria RP, Arribas E, Sun J, Leung JWT, Krishnamurthy S, Yang WT. Biopsy feasibility trial for breast cancer pathologic complete response detection after neoadjuvant chemotherapy: imaging assessment and correlation endpoints. Ann Surg Oncol. 2018;25(7):1953-1960. https://doi.org/10.1245/s10434-018-6481-y
  13. Goldstein NS, Decker D, Severson D, Schell S, Vicini F, Margolis J, Dekhne NS. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2007;110(8):1687-1696. https://doi.org/10.1002/cncr.22981
  14. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796-1804. https://doi.org/10.1200/JCO.2011.38.8595
  15. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-172.  https://doi.org/10.1016/S0140-6736(13)62422-8
  16. Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Hanusch C, Jackisch C, et al. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat. 2014;144(1):153-162.  https://doi.org/10.1007/s10549-014-2861-6
  17. Samiei S, van Nijnatten TJA, de Munck L, Keymeulen KBMI, Simons JM, Kooreman LFS, Siesling S, Lobbes MBI, Smidt ML. Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg. 2020;271(3):574-580.  https://doi.org/10.1097/SLA.0000000000003126
  18. van la Parra RF, Kuerer HM. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res. 2016;18(1):28.  https://doi.org/10.1186/s13058-016-0684-6
  19. Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol. 2011;18(11):3160-3163. https://doi.org/10.1245/s10434-011-1919-5
  20. Zhang X, Wang D, Liu Z, Wang Z, Li Q, Xu H, Zhang B, Liu T, Jin F. The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer. Quant Imaging Med Surg. 2020;10(1):197-210.  https://doi.org/10.21037/qims.2019.11.16
  21. Fowler AM, Mankoff DA, Joe BN. Imaging neoadjuvant therapy response in breast cancer. Radiology. 2017;285(2):358-375.  https://doi.org/10.1148/radiol.2017170180
  22. Mukhtar RA, Yau C, Rosen M, Tandon VJ, I-SPY 1 TRIAL and ACRIN 6657 Investigators; Hylton N, Esserman LJ. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013;20(12):3823-3830. https://doi.org/10.1245/s10434-013-3038-y
  23. McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol. 2011;18(11):3149-3154. https://doi.org/10.1245/s10434-011-1912-z
  24. Heil J, Kümmel S, Schaefgen B, Paepke S, Thomssen C, Rauch G, Ataseven B, Große R, Dreesmann V, Kühn T, et al. Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. Br J Cancer. 2015;113(11):1565-1570. https://doi.org/10.1038/bjc.2015.381
  25. Van Loevezijn AA, van der Noordaa MEM, van Werkhoven ED, Loo CE, Winter-Warnars GAO, Wiersma T, van de Vijver KK, Groen EJ, Blanken-Peeters CFJM, Zonneveld BJGL, et al. Minimally invasive complete response assessment of the breast after neoadjuvant systemic therapy for early breast cancer (MICRA trial): interim analysis of a multicenter observational cohort study. Ann Surg Oncol. 2021;28(6):3243-3253. https://doi.org/10.1245/s10434-020-09273-0
  26. Francis A, Herring K, Molyneux R, Jafri M, Trivedi S, Shaaban A, Rea DW. Abstract P5-16-14; NOSTRA PRELIM: a non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial. Cancer Res. 2017;77(4 suppl):P5-16-14.  https://doi.org/10.1158/1538-7445.SABCS16-P5-16-14
  27. Heil J, Sinn P, Richter H, Pfob A, Schaefgen B, Hennigs A, Riedel F, Thomas B, Thill M, Hahn M, et al. RESPONDER — diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast cancer — a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. BMC Cancer. 2018;18(1):851.  https://doi.org/10.1186/s12885-018-4760-4
  28. Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A Jr, et al. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg. 2018;267(5):946-951.  https://doi.org/10.1097/SLA.0000000000002313
  29. van Ramshorst MS, Loo CE, Groen EJ, Winter-Warnars GH, Wesseling J, van Duijnhoven F, Peeters MTV, Sonke GS. MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2017;164(1):99-106.  https://doi.org/10.1007/s10549-017-4254-0
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.